Drug application
NAPRELAN (NAPROXEN SODIUM)
Drugs@FDA NDA 020353 · TWI PHARMS
Key facts
| Drug name | NAPRELAN |
|---|---|
| Active ingredients | NAPROXEN SODIUM |
| Application type | NDA |
| Application number | 020353 |
| Company | TWI PHARMS |
| Dosage forms | TABLET, EXTENDED RELEASE, ORAL |
| Strength | EQ 375MG BASE |
| Marketing status | Prescription |
| TE codes | AB |
| Reference listed drug | Yes |
| Latest submission class | Type 3 - New Dosage Form |
| Latest submission status date | Jan 5, 1996 |
At a glance
- 1–9 Submissions
- 10–99 Supplements
- 1–9 Label versions
- 1–9 Products
- 1–9 Therapeutic equivalents
- No FDA letters on file
- No FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: